Cargando…
Lenvatinib-Induced Tumor Lysis Syndrome in Advanced Hepatocellular Carcinoma
This case report describes a 48-year-old man with hepatocellular carcinoma who developed tumor lysis syndrome (TLS) after 7 days of starting lenvatinib therapy. The patient was hospitalized and received appropriate interventions, including aggressive hydration, allopurinol, rasburicase, and electrol...
Autores principales: | Goyal, Manjeet Kumar, Singh, Arshdeep, Kumar Gupta, Yogesh, Kaur Dhaliwal, Kanwarpal, Sood, Ajit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479354/ https://www.ncbi.nlm.nih.gov/pubmed/37674881 http://dx.doi.org/10.14309/crj.0000000000001139 |
Ejemplares similares
-
Colonic Lipoma: A Rare Cause of Intussusception
por: Goyal, Manjeet K, et al.
Publicado: (2023) -
Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn’s disease: the Indian experience
por: Sood, Ajit, et al.
Publicado: (2020) -
Inflammatory bowel disease (IBD)-disk accurately predicts the daily life burden and parallels disease activity in patients with IBD
por: Singh, Arshdeep, et al.
Publicado: (2023) -
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021) -
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016)